Mesoblast (ASX:MSB) Gross Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Mesoblast's Gross Profit for the three months ended in Jun. 2024 was A$0.00 Mil. Mesoblast's Revenue for the three months ended in Jun. 2024 was A$0.00 Mil. Therefore, Mesoblast's Gross Margin % for the quarter that ended in Jun. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Mesoblast's Gross Margin % or its related term are showing as below:

ASX:MSB's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 60.565
* Ranked among companies with meaningful Gross Margin % only.

Mesoblast had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Mesoblast was 0.00% per year.

Mesoblast Gross Margin % Historical Data

The historical data trend for Mesoblast's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Gross Margin % Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Gross Margin %

Get a 7-Day Free Trial

Mesoblast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mesoblast's Gross Margin %

For the Biotechnology subindustry, Mesoblast's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Mesoblast's Gross Margin % falls into.

Mesoblast Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Mesoblast's Gross Margin for the fiscal year that ended in Jun. 2024 is calculated as

Gross Margin % (A: Jun. 2024 )	=	Gross Profit (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	8.9	/	8.888
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(8.888 - 0)	/	8.888
	=	N/A %

Mesoblast's Gross Margin for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )	=	Gross Profit (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Mesoblast (ASX:MSB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Mesoblast had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Mesoblast Gross Margin % Related Terms

Thank you for viewing the detailed overview of Mesoblast's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.